Gilead keeps real-world data coming on Biktarvy

19 October 2023

US biotech major Gilead Sciences (Nasdaq: GILD) has presented new long-term real-world data on its flagship medication Biktarvy (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25mg tablets, B/F/TAF).

Having moved past peak revenues for its breakthrough hepatitis C medicines, Gilead has successfully maintained growth momentum with Biktarvy, a powerful HIV once-daily triplet medication with a high barrier to resistance.

"The results presented at EACS complement the results observed in multiple Phase III clinical trials, which demonstrate the sustained efficacy, safety profile, and high barrier to resistance of Biktarvy"The product has consistently added revenues quarter-by-quarter, with annual sales exceeding $10 billion for the first time last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK